On September 30, Summit Therapeutics PLC rose 5.03% in regular trading, trading at approximately $17.21 per share, with turnover of $57.72 million. The stock continued its upward momentum following a nearly 19% surge in the prior session.

The sustained rally stems from AstraZeneca's announcement on September 29 of a $2 billion investment in convertible preferred shares in Summit, accompanied by a nonbinding clinical collaboration agreement focused on ivonescimab and sonesitatug vedotin. Under the collaboration, the two companies plan to evaluate ivonescimab in combination with multiple AstraZeneca oncology medicines, including additional antibody drug conjugates, with research costs shared jointly and clinical trials to be sponsored by AstraZeneca. Both JPMorgan and Citi expressed favorable views on the investment.

The deal represents a major validation of ivonescimab's commercial potential. Recent clinical catalysts further underpin the optimism: the Phase III HARMONi-GI1 trial demonstrated statistically significant overall survival superiority over durvalumab plus chemotherapy in advanced biliary tract cancer, while updated HARMONi-2 data showed a 27% reduction in death risk versus pembrolizumab, with consistent efficacy across Western and Asian patients.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)